Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SmoothLD
- Development stage
- Unknown
- Lead developer
- Voyageur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SmoothLD is a low-density barium sulfate suspension (60% w/v) developed by Voyageur Pharmaceuticals as a diagnostic contrast agent for gastrointestinal (GI) tract imaging. Indicated for use in CT imaging and fluoroscopy, the agent is administered orally to provide radiodensity that outlines the lumen of the GI tract, facilitating the visualization of anatomical structures and potential pathologies. Unlike many synthetic barium products, SmoothLD is produced using pharmaceutical-grade barium sulfate sourced from Voyageur's own Frances Creek deposit in British Columbia, part of a vertically integrated production model. The product was licensed by Health Canada and scheduled for commercial distribution beginning in August 2025.
- Brand names
- SmoothLD
- Other names
- barium sulfate 60% w/v oral suspension
Beyond the preview
Go deeper on SmoothLD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SmoothLD.